C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 307/91 (2006.01) A61K 31/496 (2006.01) C07D 405/12 (2006.01) C07D 405/14 (2006.01) C07D 409/12 (2006.01) C07D 409/14 (2006.01)
Patent
CA 2248269
Disclosed are compounds of general formula (I), or the pharmaceutically acceptable acid addition salts thereof, wherein: R1, R2, R3, R4 are the same or different and represent hydrogen, C1-C6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-C6 alkoxy, -O2CR', - NHCOR', -COR', -SOmR', where R' is C1-C6 alkyl and wherein m is 0, 1 or 2; or R1, R2, R3, R4 independently represent -CONR'm, or -NR'm where m is 0, 1 or 2 and R' is hydrogen or C1-C6 alkyl; R5 is hydrogen or C1-C6 alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.
L'invention porte sur des composés de formule (I) et leurs sels d'addition d'acide pharmacocompatibles. Dans ladite formule: R¿1?, R¿2?, R¿3?, R¿4? sont identiques ou différents et représentent H C¿1?-C¿6? alkyle, halogène, hydroxy, amino, cyano, nitro, trifluorométhyle, trifluorométhoxy, C¿1?-C¿6? alkoxy, -O¿2?CR', -NHCOR', -COR', -SO¿m?R', R' étant C¿1?-C¿6? alkyle et m, 0, 1 ou 2; ou bien R¿1?, R¿2?, R¿3?, R¿4? représentent indépendamment -CONR'¿m?, ou -NR'¿m?, m étant 0, 1 ou 2 et R' étant H ou C¿1?-C¿6? alkyle; R¿5? est H ou C¿1?-C¿6? alkyle; et R représente un groupe aminoalkyle. Lesdits composés peuvent servir pour le traitement de troubles affectifs tels que la schizophrénie, les états dépressifs, la maladie d'Alzheimer, les troubles de la motilité du type maladie de Parkinson ou la dystonie, et autres troubles résultant du blocage dopaminergique consécutif à l'abus de substances; ainsi que pour le traitement de troubles compulsifs obsessionnels, et celui des effets secondaires extrapyramidaux liés à l'emploi des neuroleptiques usuels.
Chen Xi
Yuan Jun
Mbm & Co.
Neurogen Corporation
LandOfFree
N-aminoalkyldibenzofurancarboxamides as dopamine receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-aminoalkyldibenzofurancarboxamides as dopamine receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-aminoalkyldibenzofurancarboxamides as dopamine receptor... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2007953